News

Article

Changing the Way Schizophrenia Is Treated

“If approved, KarXT would represent a new mechanism of action to treat schizophrenia, which would be the first new mechanism potentially in decades.”

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      “While current schizophrenia treatments do offer some benefit toward select symptoms, approximately 30% of people don’t respond, and an additional 50% only experience a partial improvement in symptoms or have challenging side effects such as weight gain, movement disorders, and somnolence.”

      In this Psychiatric Times® Mental Health Minute, Andrew C. Miller, PhD, founder and chief operating officer of Karuna Therapeutics and inventor of KarXT (xanomeline-trospium), discusses the unique mechanism of action of KarXT—Karuna’s investigational treatment for schizophrenia in adults—and provides an overview of the EMERGENT Program, 3 placebo-controlled clinical trials evaluating the treatment’s safety and efficacy.

      Dr Miller is founder and chief operating officer of Karuna Therapeutics and inventor of KarXT.

      Stay up-to-date on news related to research on promising new interventions and developments in the treatment of a wide variety of psychiatric disorders at psychiatrictimes.com.

      © 2025 MJH Life Sciences

      All rights reserved.